(Q41658924)

English

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

scientific article published on 16 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Aurélien Descazeaud

22

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Jean-Jacques Patard

30

object named as

Jean-Jacques Patard

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Jean-Christophe Bernhard

object named as

Jean-Christophe Bernhard

6

0 references

object named as

Florence Joly

7

0 references

object named as

Alain Ravaud

9

0 references

Morgan Rouprêt

20

object named as

Morgan Roupret

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

author name string

Romain Mathieu

1

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Géraldine Pignot

2

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Alexandre Ingles

3

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Maxime Crepel

4

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Pierre Bigot

5

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Laurent Guy

8

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Abdel Rahmene Azzouzi

10

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Gwenaelle Gravis

11

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Christine Chevreau

12

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Laurent Zini

13

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Hervé Lang

14

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Christian Pfister

15

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Eric Lechevallier

16

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Pierre-Olivier Fais

17

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Julien Berger

18

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Bertrand Vayleux

19

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

François Audenet

21

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Jerome Rigaud

23

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Jean-Pascal Machiels

24

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Michael Staehler

25

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Laurent Salomon

26

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Jean-Marie Ferriere

27

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Francois Kleinclauss

28

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Karim Bensalah

29

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

16 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

339.e9-15

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

The Heidelberg classification of renal cell tumours.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

ASA classification and perioperative variables as predictors of postoperative outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC)

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.05.014

7 January 2021

Identifiers

10.1016/J.UROLONC.2015.05.014

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41658924&oldid=1925638191"